Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A
MRVI
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.8B
Close$
$2.10
67.8% downside
Current Fair Value
67.8% downsideOvervalued by 67.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.80 Billion |
|---|---|
| Enterprise Value | $1.76 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.91 |
| Beta | 0.61 |
| Outstanding Shares | 147,996,000 |
Return
| Return on Equity | -37.82% |
|---|---|
| Return on Assets | -12.82% |
| Return on Invested Capital | -17.37% |
Valuation & Multiples
| P/E Ratio | -12.19 |
|---|---|
| PEG | 17.77 |
| Price to Sales | 6.53 |
| Price to Book Ratio | 3.27 |
| Enterprise Value to Revenue | 8.45 |
| Enterprise Value to EBIT | -17.96 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$48.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$43.66 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3575▼ 57.95% |
|---|---|
| Total Calls | 380,100▲ 2.67% |
| Total Puts | 135,900▼ 60.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.50%▲ 12.57% |
|---|---|
| Total Invested | $881.88M▲ 156.56% |
| Investors Holding | 187▲ 22.00% |
ESG Score
No data
About Maravai LifeSciences Holdings Inc
3 employeesMaravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are ...